rupiya.io
⠋Loading...
0%
❯ Pulling quarterly results...
IOL Chemicals & Pharmaceuticals Ltd is a Drug Manufacturers - Specialty & Generic company listed on NSE. The page combines exchange quotes, financial statements, shareholding, filings, and news so investors can review the business in one place.
IOL Chemicals & Pharmaceuticals Ltd makes money through Domestic formulations, Exports and regulated markets, Specialty or institutional sales in Drug Manufacturers - Specialty & Generic. Revenue quality depends on demand growth, margin discipline, balance-sheet strength, and the company's ability to defend its position within Pharma.
Create a free account to view momentum, moving averages, and delivery signals.
Upgrade to view volatility, drawdown, factor, and risk metrics.
| Period | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|
| Sales | ₹2,184 Cr | ₹2,217 Cr | ₹2,133 Cr | |
| Expenses | ₹1,925 Cr | ₹1,991 Cr | ₹1,902 Cr | |
| Operating Profit | ₹259 Cr | ₹226 Cr | ₹231 Cr | |
| OPM % | 12.0% | 10.0% | 11.0% | |
| Other Income | ₹17 Cr | ₹25 Cr | ₹30 Cr | |
| Depreciation | ₹43 Cr | ₹46 Cr | ₹63 Cr | |
| Interest | ₹8 Cr | ₹16 Cr | ₹16 Cr | |
| Profit Before Tax | ₹225 Cr | ₹189 Cr | ₹182 Cr | |
| Tax | ₹225 Cr | ₹189 Cr | ₹182 Cr | |
| Net Profit | ₹168 Cr | ₹139 Cr | ₹134 Cr | |
| EPS (₹) | 5.7 | 4.7 | 4.6 | |
| Dividend Payout % | 14% | 17% | 22% |
Register free to see 1 more year.
| Quarter | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | ₹523 Cr | ₹587 Cr | ₹563 Cr | ₹545 Cr | ||||||||
| Expenses | ₹481 Cr | ₹492 Cr | ₹491 Cr | ₹481 Cr | ||||||||
| Operating Profit | ₹43 Cr | ₹95 Cr | ₹73 Cr | ₹64 Cr | ||||||||
| OPM % | 8.0% | 16.0% | 13.0% | 12.0% | ||||||||
| Depreciation | ₹12 Cr | ₹12 Cr | ₹14 Cr | ₹16 Cr | ||||||||
| Interest | ₹5 Cr | ₹5 Cr | ₹4 Cr | ₹4 Cr | ||||||||
| Net Profit | ₹24 Cr | ₹65 Cr | ₹46 Cr | ₹38 Cr | ||||||||
| EPS (₹) | 0.8 | 2.2 | 1.6 | 1.3 |
Register free to see 8 more quarters.
| Period | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Equity Capital | ₹59 Cr | ₹59 Cr | ₹59 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reserves | ₹1,334 Cr | ₹1,449 Cr | ₹1,553 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Borrowings | ₹44 Cr | ₹80 Cr | ₹33 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Liabilities | ₹526 Cr | ₹435 Cr | ₹600 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Liabilities | ₹1,962 Cr | ₹2,022 Cr | ₹2,244 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fixed Assets | ₹561 Cr | ₹752 Cr | ₹933 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Investments | ₹2 Cr | ₹20 Cr | ₹20 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Receivables | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventory | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cash & Equivalents | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Assets | ₹1,294 Cr | ₹1,161 Cr | ₹1,190 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Assets | ₹1,962 Cr | ₹2,022 Cr | ₹2,244 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Register free to see 1 more year.
| Period | Operating | Investing | Financing | Net Cash Flow |
|---|---|---|---|---|
| Mar 2023 | ₹93 Cr | ₹-121 Cr | ₹-2 Cr | — |
| Mar 2024 | ₹122 Cr | ₹-120 Cr | ₹-4 Cr | — |
| Mar 2025 | ₹290 Cr | ₹-191 Cr | ₹-92 Cr | — |
Register free to see 1 more year.
No dividend history available.
No corporate actions recorded.
| Company | M.Cap | P/E | ROE | 1Y Return |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹4,51,075 Cr | 41.3 | 0.00% | +7.16% |
| Dr Reddys Laboratories Ltd | ₹1,11,310 Cr | 19.7 | +11.84% | +8.69% |
| Cipla Ltd | ₹1,15,638 Cr | 25.5 | +11.74% | -2.61% |
| Apollo Hospitals Enterprise Ltd | ₹1,16,201 Cr | 64.5 | 0.00% | +24.63% |
| Divis Laboratories Ltd | ₹1,79,486 Cr | 72.5 | 0.00% | +7.59% |
Create a free account to see institutional ownership snapshots.
Create a free account to view recent director and promoter trades.
Create a free account to view recent institutional deal activity.
Create a free account to view analyst estimate summaries.
Create a free account to view ESG risk and governance summaries.
Upgrade to view issuer ratings, instruments, outlooks, and rating history.
rupiya.io is for research and education only. Metrics shown are not investment advice. Validate with SEBI-regulated disclosures before acting.